Charles Theuer M.D. Ph.D.

Bio:

Dr. Theuer has been Chief Medical Officer at Halozyme since October 2024 where he is responsible for providing leadership and guidance to Halozyme and its partners/collaborators in subcutaneous drug development with ENHANZE® technology and auto-injectors.

Before joining Halozyme, Dr. Theuer served as Chief Executive Officer, Chief Medical Officer, and Director of TRACON Pharmaceuticals, where he worked to transform outcomes for cancer patients and optimize clinical development operations. His career includes senior medical leadership positions at TargeGen Inc. where, as Chief Medical Officer, he directed the development of Inrebic®, Pfizer where he led the clinical development of Sutent® in renal cell carcinoma and IDEC Pharmaceuticals where he oversaw clinical trials of Rituxan® and Zevalin®. He practiced as a board-certified general surgeon for more than 10 years.

Dr. Theuer earned his B.S. in Molecular Biology from the Massachusetts Institute of Technology and his M.D. from the University of California, San Francisco. He received his Ph.D. in epidemiology from the University of California, Irvine, and completed his general surgery residency at Harbor-UCLA Medical Center and post-doctoral fellowship at the National Cancer Institute. He serves as a Director of 4D Molecular Therapeutics and San Diego Squared.